Experienced in Small Cell Lung Cancer (SCLC)

Dr. Gregory Feldman

Intensive Care Medicine
Upstate Lung And Critical Care Specialists PC
151 Harold Fleming Ct, 
Spartanburg, SC 
Experienced in Small Cell Lung Cancer (SCLC)
Upstate Lung And Critical Care Specialists PC
151 Harold Fleming Ct, 
Spartanburg, SC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Gregory Feldman is an Intensive Care Medicine provider in Spartanburg, South Carolina. Dr. Feldman is rated as an Experienced provider by MediFind in the treatment of Small Cell Lung Cancer (SCLC). His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Bronchiectasis, Advanced Bronchoscopy, and Gastrostomy.

His clinical research consists of co-authoring 33 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Intensive Care Medicine
Licenses
Critical Care Medicine in SC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Upstate Lung and Critical Care Specialists PC
151 Harold Fleming Ct, Spartanburg, SC 29303
Other Locations
Midlands Pulmonary and Critical Care Specialists PC
1655 Bernardin Ave Ste 350, Columbia, SC 29204

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
A Phase 2B, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversing Ticagrelor in Subjects Aged 50 to 80 Years Old
A Phase 2B, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversing Ticagrelor in Subjects Aged 50 to 80 Years Old
Enrollment Status: Completed
Publish Date: April 08, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Other
A Randomized, Double-blind (Sponsor Unblind), Placebo-controlled, Multi-centred Phase IIa Study to Evaluate the Safety and Efficacy of 13 Weeks of Once Daily Oral Dosing of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Older Men and Post Menopausal Women With COPD and Muscle Weakness, Participating in Home Exercise
A Randomized, Double-blind (Sponsor Unblind), Placebo-controlled, Multi-centred Phase IIa Study to Evaluate the Safety and Efficacy of 13 Weeks of Once Daily Oral Dosing of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Older Men and Post Menopausal Women With COPD and Muscle Weakness, Participating in Home Exercise
Enrollment Status: Completed
Publish Date: July 15, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

33 Total Publications

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.
Journal: The New England journal of medicine
Published: September 22, 2021
Similar Doctors
Advanced in Small Cell Lung Cancer (SCLC)
Dr. Thomas Hooker
Intensive Care Medicine
Advanced in Small Cell Lung Cancer (SCLC)
Dr. Thomas Hooker
Intensive Care Medicine

Carolina Lung And Sleep At Pardee

705 6th Ave W, 
Hendersonville, NC 
 (126.4 miles away)
828-696-2570
Languages Spoken:
English
See accepted insurances

Thomas Hooker is an Intensive Care Medicine provider in Hendersonville, North Carolina. Dr. Hooker is rated as a Distinguished provider by MediFind in the treatment of Small Cell Lung Cancer (SCLC). His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Obstructive Sleep Apnea, and Lung Nodules.

Advanced in Small Cell Lung Cancer (SCLC)
Dr. Robert Ward
Intensive Care Medicine
Advanced in Small Cell Lung Cancer (SCLC)
Dr. Robert Ward
Intensive Care Medicine

Four Seasons The Care You Trust

571 S Allen Rd, 
Flat Rock, NC 
 (123.5 miles away)
828-692-6178
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Ward is an Intensive Care Medicine provider in Flat Rock, North Carolina. Dr. Ward is rated as a Distinguished provider by MediFind in the treatment of Small Cell Lung Cancer (SCLC). His top areas of expertise are Lung Metastases, Emphysema, Chronic Cough, Obstructive Sleep Apnea, and Tenotomy.

Azim E. Surka
Advanced in Small Cell Lung Cancer (SCLC)
Dr. Azim E. Surka
Pulmonary Medicine | Intensive Care Medicine
Advanced in Small Cell Lung Cancer (SCLC)
Dr. Azim E. Surka
Pulmonary Medicine | Intensive Care Medicine

Prisma Health Lung Center – Patewood

200 Patewood Drive, Suite B300, 
Greenville, SC 
 (98.7 miles away)
864-454-4200
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Azim Surka is an Intensive Care Medicine specialist and a Pulmonary Medicine provider in Greenville, South Carolina. Dr. Surka is rated as a Distinguished provider by MediFind in the treatment of Small Cell Lung Cancer (SCLC). His top areas of expertise are Lung Nodules, Small Cell Lung Cancer (SCLC), Squamous Cell Lung Carcinoma, Gastrostomy, and Advanced Bronchoscopy. Dr. Surka is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Feldman's expertise for a condition
ConditionClose
View All 32 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile